BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
Sign Up to like & getrecommendations! Published in 2019 at "Haemophilia"
DOI: 10.1111/hae.13853
Abstract: BAY 94‐9027 is an extended‒half‐life, site‐specifically PEGylated, B‐domain‒deleted recombinant factor VIII (FVIII). The PROTECT VIII main study demonstrated efficacy of bleed control using extended‐interval prophylaxis with BAY 94‐9027 for 36 weeks. read more here.
Keywords: bay 9027; efficacious well; 9027 prophylaxis; protect viii ... See more keywords
Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study
Sign Up to like & getrecommendations! Published in 2021 at "Haemophilia"
DOI: 10.1111/hae.14297
Abstract: The phase 2/3 PROTECT VIII main study demonstrated efficacy and safety of BAY 94–9027 (damoctocog alfa pegol; Jivi®), a B‐domain‐deleted recombinant factor VIII (FVIII), site‐specifically PEGylated to extend its half‐life. read more here.
Keywords: safety; bay 9027; study; efficacy ... See more keywords
Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–
Sign Up to like & getrecommendations! Published in 2024 at "Acta Haematologica"
DOI: 10.1159/000538702
Abstract: Abstract Introduction: The phase 2/3 PROTECT VIII study demonstrated long-term efficacy and safety of damoctocog alfa pegol (BAY 94-9027; Jivi®), a B-domain-deleted recombinant factor VIII (FVIII), site-specifically PEGylated to improve its pharmacokinetic profile. We report… read more here.
Keywords: protect viii; study; damoctocog alfa; alfa pegol ... See more keywords
Extended Interval Prophylaxis with Bay 94-9027 for > 4 Years Leads to Median Spontaneous Annualized Bleeding Rates < 1 in the Protect VIII Extension
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-114619
Abstract: Introduction: BAY 94-9027 is a B-domain-deleted recombinant factor VIII (FVIII) that is site-specifically PEGylated with a 60-kDa (2 × 30-kDa) polyethylene glycol (PEG) to extend its half-life. The efficacy and safety of BAY 94-9027 as… read more here.
Keywords: bay 9027; study; prophylaxis; protect viii ... See more keywords
Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-114659
Abstract: Introduction BAY 94-9027 is a B-domain-deleted recombinant factor VIII (FVIII) that is site-specifically PEGylated with a 60-kDa (2 × 30-kDa) polyethylene glycol (PEG) to extend its half-life. The efficacy and safety of BAY 94-9027 as… read more here.
Keywords: bay 9027; safety; period; protect viii ... See more keywords
Improved Bleeding Outcomes in Patients Who Switched From Sucrose-Formulated rFVIII to BAY 94-9027 Prophylaxis in PROTECT VIII
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-137565
Abstract: Background BAY 94-9027 (damoctocog alfa pegol; Jivi®) is a B-domain-deleted recombinant factor VIII (FVIII), site-specifically PEGylated to extend its half-life compared with standard-half-life FVIII products, including sucrose formulated FVIII (FVIII-FS; Kogenate® FS/Helixate® FS). A previous… read more here.
Keywords: bay; bay 9027; study; prophylaxis ... See more keywords